FDAsafety guidance83% confidence
Drug Trials Snapshots: YARTEMLEA
Source: FDA
Why This Matters
Why this matters: sets a safety guidance precedent in the same sub-indication (ild) as Rein Therapeutics.
Regulatory Analysis
YARTEMLEA is a prescription drug that is MASP-2 inhibitor indicated for the treatment of adult and pediatric patients 2 years of age and older with hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA).
Supporting Context
- Therapeutic area
- Pulmonology · Idiopathic Pulmonary Fibrosis
- Sub-indication
- Ild
Related signal: Phase 2 Study of LTI-03 in Idiopathic Pulmonary Fibrosis Patients Initiated by Rein Therapeutics